Differential use of glycoprotein IIb/IIIa inhibitors with bivalirudin in patients with STEMI undergoing PCI
Systematic review and meta-analysis published in American Journal of Cardiovascular Drugs (2024)
Abstract
AIM: The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. METHODS: Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). RESULTS: When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72-0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57-0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66-0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72-0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13-2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24-0.65; P = 0.0003). CONCLUSION: Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Meta-analysis stratifying bivalirudin trials by GPI use in STEMI PCI. Bivalirudin reduces major bleeding compared to heparin+GPI; differential use influences pooled outcomes.
Por qué esto importa para la hirudoterapia
Esta revisión sistemática y metanálisis de ocho ensayos controlados aleatorizados (n = 22.483) comparó la bivalirudina con la heparina en pacientes con IAMCEST sometidos a ICP primaria, examinando desenlaces como mortalidad, sangrado y trombosis del stent bajo distintos patrones de uso de inhibidores de la glucoproteína IIb/IIIa. La bivalirudina es un inhibidor directo de la trombina modelado a partir de la hirudina, el anticoagulante derivado de la saliva de la sanguijuela medicinal, lo que hace que este amplio metanálisis sea directamente relevante para la ASH al demostrar cómo se comporta un compuesto derivado del secretoma de la sanguijuela en la cardiología intervencionista contemporánea. Los resultados agrupados asociaron la bivalirudina con reducciones significativas de la mortalidad por todas las causas, el sangrado mayor, la muerte cardíaca y los eventos clínicos adversos netos frente a la heparina, mientras que los desenlaces de trombosis del stent difirieron en función de si el uso de GPI fue mayor o equilibrado entre los brazos del estudio. Sin embargo, al tratarse de un metanálisis de ensayos con protocolos heterogéneos y tratamientos concomitantes variables, estas asociaciones agrupadas no constituyen una prueba definitiva de superioridad, y los hallazgos divergentes sobre la trombosis del stent subrayan que los beneficios dependen del contexto clínico.
Citación
Differential use of glycoprotein IIb/IIIa inhibitors with bivalirudin in patients with STEMI undergoing PCI.
Mushahid H et al. · American journal of cardiovascular drugs, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026